Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost–Benefit Analysis

por Glover, Sarah, Borrego, Matthew E, Ray, Gretchen M, Roberts, Melissa H
Publicado 2022

Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis

por Ray, Gretchen M., Rodriguez, Chelsea, Schulman, Samantha M., Sarangarm, Preeyaporn, Bardack, Michelle, Bouchonville, Matthew F.
Publicado 2019